Cancer remains a major cause of mortality worldwide. It is estimated that the cancer death rate will be increased by 5-fold in developing countries, and the global cancer mortality is expected to increase by 104% in 2020[@b1]. Cancer is a multi-factorial disease that results from complex interactions between numerous genetic and environmental factors[@b2][@b3]. In recent years, an increasing number of studies has focused on the association between chemokine gene variants and malignancy susceptibility. Among them, the stromal cell derived factor-1 (*SDF-1*) gene, also known as CXC chemokine ligand 12 (CXCL12), has been widely studied[@b4][@b5][@b6]. The *SDF-1* gene is located on chromosome 10q11.1 and spans 10 kb[@b7]. The *SDF-1* gene mainly encodes a CXC angiogenic chemokine[@b8]. One important *SDF-1* gene polymorphism named *rs1801157* (G801A) involves a guanine to adenine (G→C) substitution at base pair 801 of the 3′-untranslated region of *SDF-1* gene[@b9].

Previous studies have indicated that *SDF-1* participates in several biological activities, including neuronal and cardiogenesis development, haematopoiesis and lymphocyte trafficking[@b10]. Furthermore, growing evidence suggests that the *SDF-1 rs1801157* polymorphism plays an important role in the pathogenesis of cancer. Razmkhah *et al*. reported that the *SDF-1 rs1801157* polymorphism increased the risk of breast and lung cancer[@b11][@b12]. Kucukgergin and co-workers showed that the *SDF-1 rs1801157* polymorphism was associated with bladder cancer susceptibility[@b13]. Hirata *et al*. reported that the *SDF-1 rs1801157* polymorphism is potentially associated with an increased risk of prostate cancer among Japanese individuals[@b14]. However, Petersen *et al*. did not identify an association between the *SDF-1 rs1801157* polymorphism and prostate cancer susceptibility[@b15], and similar negative results were also detected by Tee and colleagues[@b16].

The results of those genetic association studies were inconclusive. Moreover, a single study may be insufficient to detect a small effect of the *SDF-1 rs1801157* gene polymorphism on cancer susceptibility, especially when the sample size is relatively small. Considering the crucial role of the *SDF-1 rs1801157* gene polymorphism in the pathogenesis of cancer, we performed a meta-analysis to accurately investigate the association of the *SDF-1 rs1801157* gene polymorphism with cancer risk. Furthermore, to avoid a "false positive report", we further assessed the significant associations observed in the present meta-analysis using the false positive report probability (FPRP) test. To our knowledge, this study is most recent and accurate meta-analysis exploring the *SDF-1 rs1801157* gene polymorphism in cancer susceptibility.

Results
=======

Study characteristics
---------------------

As indicated in the flow diagram ([Fig. 1](#f1){ref-type="fig"}), 247 articles were identified after an initial search. After reading the titles and abstracts, we excluded 198 articles. The remaining 49 articles were further screened by a full-text review. Six articles were excluded because they investigated other *SDF-1* gene polymorphisms (e.g., rs2839693 and rs1065297) rather than the *rs1801157* polymorphism. Four articles were excluded because they were not case-control studies. One article was not included because it was a meta-analysis, and one article was excluded because the available data could not be extracted to further assess the effect size. Therefore, all 37 articles were identified[@b4][@b5][@b6][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44]. However, according to the results of the HWE test, 4 articles[@b18][@b38][@b39][@b44] were excluded because they did not achieve HWE in the control group. Finally, a total of 34 eligible case-control studies from 33 articles[@b4][@b5][@b6][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b40][@b41][@b42][@b43] were included in the study. Among them, 18 articles were performed on Caucasians[@b4][@b6][@b15][@b17][@b19][@b20][@b21][@b22][@b23][@b24][@b27][@b28][@b29][@b31][@b33][@b34][@b40][@b43], 13 articles on Asians[@b5][@b11][@b12][@b13][@b14][@b16][@b25][@b26][@b30][@b32][@b35][@b36][@b37], and two studies on individuals of mixed ethnicity[@b41][@b42]. In addition, based on the quality score, eleven studies were considered low quality. The characteristics of included studies are summarized in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}.

Meta-analysis results
---------------------

In total, 17,876 participants (8,062 cases and 9,814 controls) from 34 case-control studies were included in the current meta-analysis assessing the relationship between the *SDF-1 rs1801157* polymorphism and cancer risk. In the overall meta-analysis, the results suggested a significant association between the *SDF-1 rs1801157* polymorphism and cancer susceptibility in the recessive model (AA vs. AG + GG, OR: 1.28, 95% CI: 1.11--1.47, P = 0.001), a co-dominant model (AA vs. GG, OR: 1.43, 95% CI: 1.24--1.65, P \< 0.001) as assessed by a fixed-effect model (I^2^ = 47%, 49.7%, respectively) and other models (AA + AG vs. GG, OR: 1.33, 95% CI: 1.17--1.51, P \< 0.001; AG vs. GG, OR: 1.35, 95% CI: 1.19--1.54, P \< 0.001; A vs. G, OR: 1.26, 95% CI: 1.14--1.40, P \< 0.001) ([Figs 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}) as assessed by a random-effect model (I^2^ = 70.8%, 66.4%, 69.5%, respectively) ([Table 3](#t3){ref-type="table"}).

In the subgroup analyses of ethnicity, the meta-analysis results indicated a strong association between the *SDF-1 rs1801157* polymorphism and cancer susceptibility among Asians (AA + AG vs. GG, OR: 1.63, 95% CI: 1.34--1.98, P \< 0.001) and a weak association in Caucasians (AG vs. GG, OR: 1.10, 95% CI: 1.00--1.21, P = 0.05), but no association in mixed populations using different genetic models ([Table 3](#t3){ref-type="table"}). Additionally, we also conducted subgroup analyses of cancer types. As shown in [Table 3](#t3){ref-type="table"}, significant associations between the *SDF-1 rs1801157* polymorphism and breast cancer, urologic cancer, hematologic malignancy and lung cancer susceptibility were found in different genetic models. However, no association was observed between the *SDF-1 rs1801157* polymorphism and risk of head and neck cancer, gynaecological cancer and digestive system cancer ([Table 3](#t3){ref-type="table"}).

Publication bias and sensitivity analysis
-----------------------------------------

The funnel plot is a symmetrical inverted funnel ([Fig. 4](#f4){ref-type="fig"}). No publication biases were noted using Begg's (P = 0.329) and Egger's tests (P = 0.082). Additionally, to further investigate the possible source of heterogeneity, we executed a sensitivity analysis by sequentially excluding studies from the meta-analysis to investigate the influence of each study on the pooled results. The sensitivity analysis results reported that the pooled ORs were not materially altered, suggesting the stability of our meta-analysis ([Fig. 5](#f5){ref-type="fig"}).

FPRP test results
-----------------

Moreover, we further investigated the significant associations (P \< 0.05) observed in the present meta-analysis using the FPRP test. As listed in [Table 4](#t4){ref-type="table"}, the FPRP test results revealed that all 4 gene models (AA + AG vs. GG, AA vs. GG, AG vs. GG, A vs. G) of the *SDF-1 rs1801157* gene polymorphism were truly associated with cancer risk (FPRP = 0.011, 0.001, 0.008, 0.017, respectively) at an *a priori* probability level of 0.001 with an OR of 1.5, especially in Asians. In addition, according to the results of the FPRP test, we confirmed that the *SDF-1 rs1801157* gene polymorphism was only associated with lung cancer risk in the allele model (A vs. G, FPRP = 0.019), whereas the polymorphism was associated with susceptibility to urologic cancer in the dominant gene model (AA + AG vs. GG, FPRP = 0.001) at an *a priori* probability level of 0.001 and an OR of 1.5.

Discussion
==========

Cancer has high morbidity and mortality worldwide. Previous studies have suggested that cancer risk factors include an unhealthy life style, environmental pollution, radiation, infection, and immunity dysfunction[@b45][@b46][@b47]. Additionally, studies have increasingly focused on genetic factors[@b48][@b49][@b50]. In recent years, numerous studies reported an association between the *SDF-1 rs1801157* polymorphism and cancer susceptibility, but the results were inconsistent or inconclusive. In addition, a single study may lack sufficient power to detect the potentially small effect of the *SDF-1 rs1801157* polymorphism on cancer, especially when the sample size is relatively small. Meta-analysis is a useful method for investigating cancer associations with genetic factors because this method uses a quantitative approach by combining the results of different studies on the same topic, potentially providing more reliable conclusions. Thus, we conducted a pooled analysis to investigate the association of the *SDF-1 rs1801157* polymorphism and risk of cancer.

In fact, two recently published meta-analyses[@b51][@b52] investigated the association between the *SDF-1 rs1801157* gene polymorphism and cancer risk. One study[@b51] included 29 papers involving 4932 cases and 7917 controls, and another article[@b52] only included 4,435 cancer cases and 6,898 controls from 25 studies. Additionally, the two meta-analyses did not assess the quality of the included studies. Furthermore, the previous two studies did not use the FPRP test to explore truly significant associations, and the results of those studies were potentially unable to reflect the true association between the *SDF-1 rs1801157* gene polymorphism and cancer risk. Therefore, we performed a meta-analysis and FPRP test to assess the association between the *SDF-1 rs1801157* gene polymorphism and cancer risk.

In total, 8,062 cases and 9,814 controls were included in the current meta-analysis. Based on our overall meta-analysis and FPRP tests, we found that the *SDF-1 rs1801157* polymorphism obviously increased the risk of cancer. Additionally, we identified significant heterogeneity between studies in the present meta-analysis. Although heterogeneity can be considered using the random-effect model, heterogeneity increases the probability of type-I errors. The following factors may have contributed to the significant heterogeneity: 1) different demographic and genetic characteristics of Caucasian, Asian and mixed populations; 2) different types of cancer may be caused by different mechanisms; 3) different stages of cancer in each study among the studied cancer patients; 4) different genotyping methods of each study; and 5) different qualities among included studies.

Hence, to identify the cause of heterogeneity, we conducted subgroup analyses based on ethnicity and cancer type. The results suggested that the *SDF-1 rs1801157* gene polymorphism strongly increased the cancer risk among Asians, whereas the heterozygote genotype (AG) of the *SDF-1 rs1801157* gene polymorphism only weakly increased cancer susceptibility in Caucasians. Unfortunately, the *SDF-1 rs1801157* gene polymorphism did not increase or decrease the cancer risk among mixed populations. Furthermore, the results of sub-group analyses after stratification based on cancer type indicated that the *SDF-1 rs1801157* polymorphism increased the risk of breast cancer, urologic cancer, lung cancer, head and neck cancer, and haematological malignancies. However, the *SDF-1 rs1801157* polymorphism did not influence gynaecological cancer and digestive system cancer susceptibility. Despite the fact that the heterogeneity was still detected when we performed stratified analyses based on ethnicity and cancer type, the subgroup analyses may provide more precise results compared with the overall analysis.

Several previous studies indicated that the published "statistically significant" results for genetic variants were false-positive findings, even in large and well-designed studies[@b53][@b54]. Fortunately, we could use the FPRP test to estimate true significant associations in the current meta-analysis. The FPRP is calculated from the statistical power of the test, the observed p-value, and a given *a priori* probability for the association.

Therefore, based on the positive results of the current meta-analysis, we further investigated whether a significant association between the *SDF-1 rs1801157* gene polymorphism and cancer risk is "noteworthy". Interestingly, the FPRP test results revealed that the *SDF-1 rs1801157* gene polymorphism actually increased cancer susceptibility. Additionally, the FPRP test also demonstrated that the *SDF-1 rs1801157* gene polymorphism could increase cancer risk among Asians, but it did not increase cancer risk in Caucasians. Moreover, the results of the FPRP test confirmed that the *SDF-1 rs1801157* gene polymorphism increased the risk of lung cancer and urologic cancer. Surprisingly, the significant associations with breast cancer, head and neck cancer, and haematological malignancies in the present meta-analysis were false positive at the a priori probability level of 0.001 and an OR of 1.5. Some of the discoveries may be false-positive findings due to the limited sample size in each stratum, so it is important to perform FPRP analysis to avoid these findings, especially when the sample size is not of sufficient size.

The mechanism by which the *SDF-1 rs1801157* polymorphism affects cancer risk is unclear. Previous studies indicated that *SDF-1* is a chemokine that plays a pivotal role in different stages of cancer development and metastasis[@b55][@b56]. Combined with previous results[@b57] and our present meta-analysis results, we put forward a simple hypothesis that the *SDF-1 rs1801157* polymorphism, which has a G \> A transition in the 3′-UTR, may have an important regulatory function of up-regulating *SDF-1* production and the high serum concentrations of *SDF-1* might contribute to cancer susceptibility. Finally, people who carried the variant A allele are more likely to develop cancer, especially urologic cancer and lung cancer.

Several limitations in the present meta-analysis should be noted. First, the published studies include small sample sizes, and only published articles were included in a few databases. Thus, these limitations might lead to additional biases or overall overestimated associations. Moreover, a language bias potentially also occurred because the including articles were only published in English and Chinese. Second, given the lack sufficient data for each included study, we failed to perform further subgroup analysis to investigate the risk factors of cancer, such as gender, gene-environment/gene-gene interactions, life style and age. Third, a small number of studies were included in the subgroup analysis to investigate the association between the *SDF-1 rs1801157* polymorphism and head and neck cancer risk, so we must be cautious when referring to the pooled results. A study with larger samples is needed to confirm the results in the future. Despite these limitations, we minimized the likelihood of bias throughout the entire process by creating a detailed protocol and carefully performing study identification, statistical analysis and data selection. Thus, the reliability of the results is guaranteed.

In conclusion, the current study suggested that the *SDF-1 rs1801157* polymorphism may contribute to the risk of cancer in Asians. In particular, the polymorphism could increase urologic and lung cancer susceptibility. More well-designed studies with larger sample sizes focusing on ethnicities or cancer types should be conducted to confirm the results in the future.

Methods
=======

Study selection
---------------

A systematic literature search of the PubMed, Embase, and Wanfang databases and the China National Knowledge Internet (CNKI) was performed to identify studies involving the relationship between the *SDF-1 rs1801157* gene polymorphism and cancer susceptibility, with the last updated search being conducted on May 14, 2015. The following key words were used: (stromal cell derived factor-1 OR *SDF-1* OR CXC chemokine ligand 12 OR CXCL12) AND (cancer OR tumour OR neoplasm OR malignancy OR leukaemia OR myeloma OR sarcoma OR lymphoma) AND (polymorphism OR mutation OR variant). The language was restricted to English and Chinese.

Inclusion and exclusive criteria
--------------------------------

The inclusion criteria were defined as follows: 1) the study should be a case-control study; 2) the association between the *SDF-1 rs1801157* polymorphism and cancer risk should be evaluated; 3) the available genotype or allele frequencies for counting the odds ratio (OR) and 95% confidence interval (CI) should be provided in the study; 4) the study should evaluate humans; and 5) the genotype distributions of control cohorts should be in with Hardy-Weinberg equilibrium (HWE). The following exclusive criteria were adopted: 1) the study was not designed as a case-control study; 2) review, abstract or overlapping study; and 3) the study cannot provide available genotype or allele frequencies for determining the effect size.

Quality score evaluation
------------------------

The qualities of included studies were assessed by the Newcastle-Ottawa Scale (case control study). The scale estimates quality based on three aspects: selection, comparability and exposure in the study. The total score ranged from 0 to 9, and a score greater than 6 was considered to represent high quality. In addition, we assessed the quality of the studies in a consensus meeting with all authors.

Data extraction
---------------

The independent authors (Xiang Tong and Huajiang Deng) collected detailed data from each study according to the inclusive criteria. If a disagreement was encountered, the third author (Xixi Wang) evaluated the articles. For each study, the first author, publication year, country, ethnicity, number of case and control groups, type of cancer, genotype and allele distribution, and genotyping method were extracted. The information is listed in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}.

Statistical methods
-------------------

The OR and 95% CI were used to estimate the effect strength of association between the *SDF-1 rs1801157* polymorphism and cancer susceptibility. We calculated heterogeneity using the χ^2^-based Q-test and I-squared (I^2^) statistics tests. The pooled OR was assessed by the random-effect model when the heterogeneity was considered to be statistically significant (I^2^ \> 50% and P  \< 0.10); alternatively, the fixed-effect model was applied. We explored the association between the *SDF-1 rs1801157* polymorphism and cancer risk in different gene models (AA + AG vs. GG, AA vs. AG + GG, AA vs. GG, AG vs. GG and A vs. G). To evaluate the effects of ethnicity and type of cancer, we also performed subgroup analyses based on ethnicity group and type of cancer.

In addition, to evaluate whether significant associations (P \< 0.05) detected in the present study are "noteworthy", we further calculated the FPRP value at a probability level of 0.001 and an OR of 1.5 [@b58]. As suggested by the previous study[@b59], we set a FPRP cut-off value of 0.2, and only FPRP results \< 0.2 were considered to be "noteworthy". Publication bias was assessed by several methods. A visual inspection of asymmetry in funnel plots was performed. Furthermore, the Begger's and Egger's tests were used to assess the publication bias[@b60]. Additionally, HWE was assessed in each study using the Chi-square before the present meta-analysis was performed. All analyses were conducted using STATA 11.0 software.
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###### Characteristics of case-control studies included in the meta-analysis.

  First author          Year  Country     Ethnicity   Type        Sample size  Genotyping method   HWE    Score
  -------------------- ------ ----------- ----------- ---------- ------------- ------------------- ----- -------
  Bodelon C             2013  USA         Caucasian   BC            840/801    IGGMP               Yes      6
  Bracci PM             2010  USA + UK    Caucasian   NHL           255/511    IGGMP               Yes      8
  Cacina C              2012  Turkey      Asian       EC            113/139    PCR-RFLP            Yes      6
  Cai C                 2013  China       Asian       RC            322/402    PCR-RFLP            Yes      7
  de Lourdes Perim A    2013  Brazil      Caucasian   ALL            54/58     PCR-RFLP            Yes      6
  de Oliveira CE        2007  Brazil      Caucasian   CML            25/60     PCR-RFLP            Yes      5
  de Oliveira KB        2009  Brazil      Caucasian   BC            103/97     PCR-RFLP            Yes      5
  de Oliveira KB        2010  Brazil      Caucasian   NHL + HL      106/90     PCR-RFLP            Yes      5
  Dimberg J             2007  Sweden      Caucasian   CRC           151/141    PCR-RFLP            Yes      5
  Gawron AJ             2011  Poland      Caucasian   GC            292/414    TaqMan              Yes      7
  Hidalgo-Pascual M     2007  Spain       Caucasian   CRC           349/516    Real-time PCR       Yes      6
  Hirata H              2007  Japan       Asian       PC            167/167    PCR-RFLP            Yes      5
  Isman FK              2012  Turkey      Asian       PC            152/149    PCR-RFLP            Yes      7
  Khademi B             2008  Iran        Asian       HC + NC       156/262    PCR-RFLP            Yes      6
  Kontogianni P         2013  Greece      Caucasian   BC            261/480    PCR-RFLP            Yes      6
  Kruszyna L            2010  Poland      Caucasian   BC            193/199    PCR-RFLP            Yes      6
  Kruszyna L            2010  Poland      Caucasian   LAC           118/250    PCR-RFLP            Yes      6
  Kucukgergin C         2012  Turkey      Asian       BLC           142/197    PCR-RFLP            Yes      7
  Lee YL                2011  China       Asian       LC            247/328    PCR-RFLP            Yes      7
  Liarmakopoulos E      2013  Greece      Caucasian   GC            88/480     PCR-RFLP            Yes      6
  Lin GT                2009  China       Asian       BC            220/334    PCR-RFLP            Yes      4
  Maley SN              2009  USA         Caucasian   CC            899/820    TaqMan              Yes      7
  Mazur G               2013  Poland      Caucasian   MM             54/75     PCR-RFLP            Yes      4
  Pemberton NC          2006  UK          Caucasian   CLL           323/108    PCR-RFLP            Yes      5
  Petersen DC           2008  Australia   Caucasian   PC            815/727    TaqMan              Yes      6
  Razmkhah M            2013  Iran        Asian       GC + CC       233/262    PCR-RFLP            Yes      4
  Razmkhah M            2005  Iran        Asian       BC            278/181    PCR-RFLP            Yes      6
  Razmkhah M            2005  Iran        Asian       LC            72/262     PCR-RFLP            Yes      4
  Shi MD                2013  China       Asian       CRC           258/300    DHPLC               Yes      5
  Singh V               2014  India       Asian       BLC           200/200    PCR-RFLP            Yes      7
  Tee YT                2012  China       Asian       CC            137/337    PCR-RFLP            Yes      7
  Vairaktaris E         2008  Europe      Caucasian   OC            159/101    PCR-RFLP            Yes      6
  Vázquez-Lavista LG    2009  Mexico      Mixed       BLC           47/126     PCR-RFLP            Yes      7
  Wong HL               2010  USA         Mixed       NHL           233/240    TaqMan              Yes      7

BC = breast cancer; EC = endometrial cancer; RC = renal cancer; ALL = acute lymphatic leukaemia; CML = chronic myeloid leukaemia; NHL non-Hodgkin's lymphoma; HL = Hodgkin's lymphoma; CRC = colorectal cancer; GC = gastric cancer; PC = prostate cancer; HC = head cancer; NC = neck cancer; LAC = laryngeal cancer; BLC = bladder cancer; LC = lung cancer; CC = cervical cancer; MM = multiple myeloma; CLL = chronic lymphocytic leukaemia; OC = ovarian cancer; IGGMP = Illumina Golden Gate multiplex platform; PCR-RFLP = polymerase chain reaction-restricted fragment length polymorphism; DHPLC  = denaturing high performance liquid chromatography.

###### Distributions of the *SDF-1 rs1801157* allele and genotypes in cases and controls.

  First author          Year   Case   Control                                             
  -------------------- ------ ------ --------- ----- ----- ------ ----- ----- ----- ----- ------
  Bodelon C             2013    29      288     523   346   1334   35    251   515   321   1281
  Bracci PM             2010    6       85      164   97    413    14    161   336   189   833
  Cacina C              2012    12      52      49    76    150     6    64    69    76    202
  Cai C                 2013    61      111     150   233   411    29    136   237   194   610
  de Lourdes Perim A    2013    3       18      33    24     84     1    11    46    13    103
  de Oliveira CE        2007    4       11      10    19     31     3    18    39    24     96
  de Oliveira KB        2009    3       41      59    47    159     4    32    61    40    154
  de Oliveira KB        2010    5       43      58    53    159     5    26    59    36    144
  Dimberg J             2007    5       62      84    72    230     4    56    81    64    218
  Gawron AJ             2011    99      193     NA    NA    156    258   NA    NA         
  Hidalgo-Pascual M     2007    9       128     212   146   552    25    172   319   222   810
  Hirata H              2007    17      78      72    112   222    13    63    91    89    245
  Isman FK              2012    17      66      69    100   204    22    57    70    101   197
  Khademi B             2008    8       84      64    100   212    20    97    145   137   387
  Kontogianni P         2013    29      118     114   176   346    35    198   247   268   692
  Kruszyna L            2010    9       61      123   79    307     5    58    136   68    330
  Kruszyna L            2010    3       46      69    52    184     2    67    181   71    429
  Kucukgergin C         2012    26      58      58    110   174    23    80    94    126   268
  Lee YL                2011    36      112     99    184   310    21    136   171   178   478
  Liarmakopoulos E      2013    6       43      39    55    121    46    229   205   321   639
  Lin GT                2009    16      98      106   130   310    23    136   175   182   486
  Maley SN              2009    30      276     593   336   1462   23    274   523   320   1320
  Mazur G               2013    1       13      39    15     91     1    21    53    23    127
  Pemberton NC          2006   114      209     NA    NA     43    65    NA    NA         
  Petersen DC           2008    NA      NA      NA    326   1304   NA    NA    NA    276   1178
  Razmkhah M            2013    18      87      128   123   343     8    39    62    55    163
  Razmkhah M            2005    34      139     105   207   349    13    67    101   93    269
  Razmkhah M            2005    9       38      25    56     88    20    97    145   137   387
  Shi MD                2013    4       113     141   121   395     0    52    248   52    548
  Singh V               2014    9       132     59    150   250    16    83    101   115   285
  Tee YT                2012    16      58      63    90    184    33    140   164   206   468
  Vairaktaris E         2008    4       51      104   59    259     5    41    55    51    151
  Vázquez-Lavista LG    2009    3       15      29    21     73     4    39    83    47    205
  Wong HL               2010    7       78      148   92    374    13    64    163   90    390

NA = not available.

###### Summary the results of the total and subgroup analyses in different genetic models.

  Variables                   AA + AG vs. GG   AA vs. AG + GG   AA vs. GG   AG vs. GG    A vs. G                                                                                              
  -------------------------- ---------------- ---------------- ----------- ----------- ------------ --------- ------ ------------ --------- ------ ------------ --------- ------ ------------ ---------
  Total                            1.33          1.17--1.51      \<0.001      1.28      1.11--1.47    0.001    1.43   1.24--1.65   \<0.001   1.35   1.19--1.54   \<0.001   1.26   1.14--1.40   \<0.001
   Ethnicities                                                                                                                                                                                
   Caucasian                       1.07          0.98--1.16       0.15        1.03      0.82--1.29    0.81     1.07   0.85--1.35    0.55     1.10   1.00--1.21    0.05     1.07   1.00--1.15    0.06
   Asian                           1.63          1.34--1.98      \<0.001      1.42      1.05--1.93    0.02     1.71   1.28--2.30   \<0.001   1.58   1.28--1.95   \<0.001   1.45   1.25--1.68   \<0.001
   Mixed                           1.21          0.87--1.69       0.26        0.92      0.25--3.34    0.90     0.82   0.37--1.81    0.62     1.28   0.90--1.82    0.16     1.11   0.83--1.47    0.48
  Types                                                                                                                                                                                       
   Breast cancer                   1.26          1.11--1.44      \<0.001      1.21      0.93--1.59    0.16     1.36   1.03--1.79    0.03     1.26   1.10--1.44   \<0.001   1.20   1.08--1.33   \<0.001
   Gynaecological cancer           0.98          0.83--1.16       0.81        1.36      0.93--1.99    0.12     1.36   0.92--2.01    0.13     0.94   0.79--1.12    0.52     1.03   0.89--1.18    0.71
   Urologic cancer                 1.56          1.32--1.85      \<0.001      1.34      0.75--2.38    0.32     1.62   0.97--2.69    0.06     1.46   1.10--1.93   \<0.001   1.31   1.09--1.57   \<0.001
   Digestive system cancer         1.25          0.79--1.98       0.34        0.83      0.55--1.27    0.40     0.88   0.57--1.35    0.55     1.38   0.82--2.33    0.23     1.26   0.80--1.97    0.32
   Hematologic malignancy          1.17          0.97--1.41       0.09        0.95      0.57--1.59    0.98     1.06   0.63--1.78    0.83     1.29   1.04--1.59    0.02     1.18   0.99--1.40    0.07
   Lung cancer                     1.80          1.36--2.39      \<0.001      2.24      1.41--3.57   \<0.001   2.86   1.75--4.69   \<0.001   1.62   1.20--2.18   \<0.001   1.65   1.34--2.04   \<0.001
   Head and neck cancer            1.3           0.68--2.48       0.43        0.76      0.40--1.46    0.41     0.92   0.47--1.80    0.81     1.35   0.70--1.61    0.37     1.16   0.71--1.91    0.55

OR = odds ratio; CI = confidence interval.

###### The results of the FPRP tests in each gene models.

  Gene models                   OR (95% CI)      Power   Prior Probability  = 0.001
  ------------------------- ------------------- ------- ----------------------------
  Total                      1.33 (1.17--1.51)   0.968             0.011
  Asians                     1.63 (1.34--1.98)   0.201             0.004
  Breast cancer              1.26 (1.11--1.44)   0.995              0.41
  Urologic cancer            1.56 (1.32--1.85)   0.326             0.001
  Lung cancer                1.80 (1.36--2.39)   0.104             0.318
  AA vs. AG + GG                                        
   Total                     1.28 (1.11--1.47)   0.988             0.323
   Asian                     1.42 (1.05--1.93)   0.637             0.975
   Lung cancer               2.24 (1.41--3.57)   0.046             0.938
  AA vs. GG                                             
   Total                     1.43 (1.24--1.65)   0.744             0.001
   Asians                    1.71 (1.28--2.30)   0.193             0.668
   Breast cancer             1.36 (1.03--1.79)   0.758             0.974
   Lung cancer               2.86 (1.75--4.69)   0.005             0.856
  AG vs. GG                                             
   Total                     1.35 (1.19--1.54)   0.942             0.008
   Caucasians                1.10 (1.00--1.21)     1               0.980
   Asians                    1.58 (1.28--1.95)   0.314             0.061
   Breast cancer             1.26 (1.10--1.44)   0.995             0.410
   Urologic cancer           1.46 (1.10--1.93)   0.575             0.932
   Hematologic malignancy    1.29 (1.04--1.59)   0.921             0.949
   Lung cancer               1.62 (1.20--2.18)   0.306             0.826
  A vs. G                                               
   Total                     1.26 (1.14--1.40)   0.999             0.017
   Asians                    1.45 (1.25--1.68)   0.674             0.001
   Breast cancer             1.20 (1.08--1.33)     1               0.339
   Urologic cancer           1.31 (1.09--1.57)   0.929             0.788
   Lung cancer               1.65 (1.34--2.04)   0.189             0.019

OR = odds ratio; FPRP = false positive report probability.

[^1]: These authors contributed equally to this work.
